These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 27095555

  • 21. Downregulated formyl peptide receptor 2 expression in the epileptogenic foci of patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
    Huang K, Wang Z, He Z, Li Y, Li S, Shen K, Zhu G, Liu Z, Lv S, Zhang C, Yang H, Yang X, Liu S.
    Immun Inflamm Dis; 2022 Nov; 10(11):e706. PubMed ID: 36301030
    [Abstract] [Full Text] [Related]

  • 22. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions.
    Koning N, Bö L, Hoek RM, Huitinga I.
    Ann Neurol; 2007 Nov; 62(5):504-14. PubMed ID: 17879969
    [Abstract] [Full Text] [Related]

  • 23. Expression of pannexin 1 and 2 in cortical lesions from intractable epilepsy patients with focal cortical dysplasia.
    Li S, Zang Z, He J, Chen X, Yu S, Pei Y, Hou Z, An N, Yang H, Zhang C, Liu S.
    Oncotarget; 2017 Jan 24; 8(4):6883-6895. PubMed ID: 28036289
    [Abstract] [Full Text] [Related]

  • 24. Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions.
    Prabowo AS, Iyer AM, Anink JJ, Spliet WG, van Rijen PC, Aronica E.
    J Neuroinflammation; 2013 Jan 24; 10():12. PubMed ID: 23347564
    [Abstract] [Full Text] [Related]

  • 25. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
    Li S, Yu S, Zhang C, Shu H, Liu S, An N, Yang M, Yin Q, Yang H.
    Brain Res; 2012 May 09; 1453():46-55. PubMed ID: 22459050
    [Abstract] [Full Text] [Related]

  • 26. Dysregulation of the (immuno)proteasome pathway in malformations of cortical development.
    van Scheppingen J, Broekaart DW, Scholl T, Zuidberg MR, Anink JJ, Spliet WG, van Rijen PC, Czech T, Hainfellner JA, Feucht M, Mühlebner A, van Vliet EA, Aronica E.
    J Neuroinflammation; 2016 Aug 26; 13(1):202. PubMed ID: 27566410
    [Abstract] [Full Text] [Related]

  • 27. Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb.
    Shu HF, Yu SX, Zhang CQ, Liu SY, Wu KF, Zang ZL, Yang H, Zhou SW, Yin Q.
    Brain Dev; 2013 Mar 26; 35(3):252-60. PubMed ID: 22647236
    [Abstract] [Full Text] [Related]

  • 28. Expression of the Nogo-A system in cortical lesions of pediatric patients with tuberous sclerosis complex and focal cortical dysplasia type IIb.
    Yu SX, Li S, Shu HF, Zhang CQ, Liu SY, Yang H.
    J Neuropathol Exp Neurol; 2012 Jul 26; 71(7):665-77. PubMed ID: 22710967
    [Abstract] [Full Text] [Related]

  • 29. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
    Zimmer TS, Korotkov A, Zwakenberg S, Jansen FE, Zwartkruis FJT, Rensing NR, Wong M, Mühlebner A, van Vliet EA, Aronica E, Mills JD.
    Brain Pathol; 2021 Sep 26; 31(5):e12949. PubMed ID: 33786950
    [Abstract] [Full Text] [Related]

  • 30. Clinical, imaging, and immunohistochemical characteristics of focal cortical dysplasia Type II extratemporal epilepsies in children: analyses of an institutional case series.
    Knerlich-Lukoschus F, Connolly MB, Hendson G, Steinbok P, Dunham C.
    J Neurosurg Pediatr; 2017 Feb 26; 19(2):182-195. PubMed ID: 27885945
    [Abstract] [Full Text] [Related]

  • 31. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
    Patil VV, Guzman M, Carter AN, Rathore G, Yoshor D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE.
    Neuropathology; 2016 Apr 26; 36(2):146-56. PubMed ID: 26381727
    [Abstract] [Full Text] [Related]

  • 32. Expression Patterns of TRPC1 in Cortical Lesions from Patients with Focal Cortical Dysplasia.
    Zang Z, Li S, Zhang W, Chen X, Zheng D, Shu H, Guo W, Zhao B, Shen K, Wei Y, Zheng X, Liu S, Yang H.
    J Mol Neurosci; 2015 Oct 26; 57(2):265-72. PubMed ID: 26280213
    [Abstract] [Full Text] [Related]

  • 33. Expression profiles of α-synuclein in cortical lesions of patients with FCD IIb and TSC, and FCD rats.
    Zhang L, Huang J, Dai L, Zhu G, Yang XL, He Z, Li YH, Yang H, Zhang CQ, Shen KF, Liang P.
    Front Neurol; 2023 Oct 26; 14():1255097. PubMed ID: 38020594
    [Abstract] [Full Text] [Related]

  • 34. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
    Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E.
    Epilepsia; 2009 Jun 26; 50(6):1409-18. PubMed ID: 19220410
    [Abstract] [Full Text] [Related]

  • 35. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.
    Hernangómez M, Mestre L, Correa FG, Loría F, Mecha M, Iñigo PM, Docagne F, Williams RO, Borrell J, Guaza C.
    Glia; 2012 Sep 26; 60(9):1437-50. PubMed ID: 22653796
    [Abstract] [Full Text] [Related]

  • 36. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation.
    Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF.
    Exp Neurol; 2009 Jan 26; 215(1):5-19. PubMed ID: 18938162
    [Abstract] [Full Text] [Related]

  • 37. Doublecortin immunoreactivity in giant cells of tuberous sclerosis and focal cortical dysplasia.
    Mizuguchi M, Yamanouchi H, Becker LE, Itoh M, Takashima S.
    Acta Neuropathol; 2002 Oct 26; 104(4):418-24. PubMed ID: 12200630
    [Abstract] [Full Text] [Related]

  • 38. Analysis of chromosomal instability in focal cortical dysplasia of Taylor's balloon cell type.
    Fassunke J, Blümcke I, Lahl R, Elger CE, Schramm J, Merkelbach-Bruse S, Mathiak M, Wiestler OD, Becker AJ.
    Acta Neuropathol; 2004 Aug 26; 108(2):129-34. PubMed ID: 15235806
    [Abstract] [Full Text] [Related]

  • 39. FCD Type II and mTOR pathway: Evidence for different mechanisms involved in the pathogenesis of dysmorphic neurons.
    Rossini L, Villani F, Granata T, Tassi L, Tringali G, Cardinale F, Aronica E, Spreafico R, Garbelli R.
    Epilepsy Res; 2017 Jan 26; 129():146-156. PubMed ID: 28056425
    [Abstract] [Full Text] [Related]

  • 40. The immune inhibitory complex CD200/CD200R is developmentally regulated in the mouse brain.
    Shrivastava K, Gonzalez P, Acarin L.
    J Comp Neurol; 2012 Aug 15; 520(12):2657-75. PubMed ID: 22323214
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.